Hepatic Epithelioid Hemangioendothelioma is a rare malignancy arising from the vascular endothelial cells within the liver. Historically the disease is characterized as bad treatment of choice responds to both chemotherapy and radiation therapy, liver resection or transplant if feasible. For patients with advanced disease reports on long-term therapeutic benefits of Conventional cytotoxic treatment are very limited. Due to the rarity of this malignancy there are no structured therapeutic research, but a small number of cases still respond well to treatment with inhibitors of angiogenesis reported. Thalidomide was originally as an anti emetic but a potent inhibitor of vascular neo Genesis is developed, and promoting the malignant vascular endothelial cells could offer potential in the treatment of hepatic Epithelioid Hemangioendothelioma by blocking.
We describe the case Caucasian British woman, at the age of 53 years of hepatic mass malignant Lymphadenopathy, pulmonary metastases certified as hepatic Epithelioid Hemangioendothelioma on biopsy were presented. After unproductive treatment with interferon our patients on Thalidomide started 400 mg daily. It has successfully manages to therapy for the last seven years was and remained asymptomatic with radiologically stable disease and minimum treatment-related side effects.
There is currently no standard treatment for advanced hepatic Epithelioid Hemangioendothelioma. The role for thalidomide and potentially other inhibitors of vascular neo Genesis helps the treatment of patients with metastatic hepatic Epithelioid Hemangioendothelioma our case.
